Home

Insights

Jagsonpal Pharmaceuticals Ltd P/E Ratio

Jagsonpal Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 0.1 Cr

Volume transacted

stocks purchased

1.8 K

stocks traded

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

PE

40

Last updated : 20 Jun 06:44 AM

Key Highlights

    The P/E Ratio of Jagsonpal Pharmaceuticals Ltd is 40 as of 20 Jun 06:44 AM .a1#The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 9.6 on March 2019 to 28.4 on March 2023 . This represents a CAGR of 24.23% over 5 years. a1#The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 338 as of 20 Jun 12:07 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 101.4. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 68.9 crore on March 2019 to ₹ 759.48 crore on March 2023 . This represents a CAGR of 61.61% over 5 years. a1#The Revenue of Jagsonpal Pharmaceuticals Ltd changed from ₹ 60.91 crore to ₹ 45.97 crore over 8 quarters. This represents a CAGR of -13.13% a1#The EBITDA of Jagsonpal Pharmaceuticals Ltd changed from ₹ 4.03 crore to ₹ 5.16 crore over 8 quarters. This represents a CAGR of 13.15% a1#The Net Profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 2.92 crore to ₹ 3.55 crore over 8 quarters. This represents a CAGR of 10.26% a1#The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 9.07 % on March 2019 to 49.03 % on March 2023 . This represents a CAGR of 40.14% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '199.6
Mar '205.8
Mar '2112.2
Mar '2243.6
Mar '2328.4

Fundamental Metrics

Market Cap

899 Cr

EPS

8.5

P/E Ratio (TTM) *

40.0

P/B Ratio (TTM) *

4.8

Day’s High

341.0

Day’s Low

337.15

DTE *

0.0

ROE *

12.0

52 Week High

513.9

52 Week Low

270.05

ROCE *

15.6

* All values are consolidated

Last Updated time: 20 Jun 06:44 AM

* All values are consolidated

Last Updated time: 20 Jun 06:44 AM

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

PRICE

338

-2.25 (-0.66%)

stock direction

Last updated : 20 Jun 12:07

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Jagsonpal Pharmaceuticals Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value

Market Value

900

Asset Value

165

4.5 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
Sun Pharmaceuticals Industries Ltd36360,896
Cipla Ltd29125,905
Divis Laboratories Ltd74118,864
Zydus Lifesciences Ltd28108,024
Dr Reddys Laboratories Ltd1799,341
Jagsonpal Pharmaceuticals Ltd40899

Key Valuation Metric

Earnings

22 Cr

40.0 X

PE Ratio

Market Cap

₹899.55Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

22 Cr

40.0 X

PE Ratio

Market Cap

₹899.55Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '1969
Mar '2046
Mar '21208
Mar '22822
Mar '23759

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '2261
Sep '2262
Dec '2262
Mar '2358
Jun '2362
Sep '2360
Dec '2350
Mar '2446

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '224
Sep '2214
Dec '2210
Mar '238
Jun '2311
Sep '2311
Dec '236
Mar '245

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '223
Sep '2210
Dec '228
Mar '236
Jun '237
Sep '237
Dec '234
Mar '244

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '199
Mar '2017
Mar '2115
Mar '2256
Mar '2349

* All values are a in %

About Jagsonpal Pharmaceuticals Ltd

About Jagsonpal Pharmaceuticals Ltd

    Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity. The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the product market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.

Jagsonpal Pharmaceuticals Ltd News Hub

News

Jagsonpal Pharmaceuticals completes acquisition of India and Bhutan biz of Yash Pharma

Jagsonpal Pharmaceuticals completed the acquisition of India & Bhutan business of Yash Pha...

Read more

31 May 202414:15

News

Board of Jagsonpal Pharmaceuticals recommends final dividend

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meet...

Read more

21 May 202409:56

News

Jagsonpal Pharmaceuticals Ltd leads losers in 'B' group

Pakka Ltd, IFGL Refractories Ltd, Mangalore Chemicals & Fertilizers Ltd and SBC Exports Lt...

Read more

05 Feb 202414:45

News

Jagsonpal Pharmaceuticals to declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

27 Jan 202416:27

News

Jagsonpal Pharmaceuticals allots 89,794 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 89,794 equity shares under ESOP on 04 December 2023...

Read more

04 Dec 202318:16

News

Board of Jagsonpal Pharmaceuticals approves divestment of its Faridabad unit

The Board of Jagsonpal Pharmaceuticals at its meeting held on 03 November 2023 has approve...

Read more

03 Nov 202315:06

Product Composition by Percentage (Revenue)

FAQs for PE of Jagsonpal Pharmaceuticals Ltd

What is Jagsonpal Pharmaceuticals Ltd current share price?

The current market price of Jagsonpal Pharmaceuticals Ltd as of June 20, 2024 is ₹338.00.

What is Jagsonpal Pharmaceuticals Ltd's market cap?

Jagsonpal Pharmaceuticals Ltd's market capitalisation stood at ₹899 Cr as of June 20, 2024

What are Jagsonpal Pharmaceuticals Ltd's total net assets?

According to Jagsonpal Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹164.6 Cr.

Is Jagsonpal Pharmaceuticals Ltd making a profit or loss?

Jagsonpal Pharmaceuticals Ltd's net Profit as of June 20, 2024 is close to ₹22 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199